Why the study?
RAAS dysregulation in sepsis contributes to organ failure and outcomes, and understanding its pathophysiology has led to using exogenous angiotensin II as a therapeutic agent.
What is the role of RAAS modulation and exogenous angiotensin II in patients with sepsis?
What is the role of RAAS modulation and exogenous angiotensin II in patients with sepsis?
This expert panel review provides guidance on the use of exogenous angiotensin II for RAAS modulation in patients with septic shock.
This is the authors' abstract. We don't add key points for this paper.
Dysregulation of the renin-angiotensin-aldosterone-system (RAAS) in sepsis is a complex and early phenomenon with a likely significant contribution to organ failure and patient outcomes. A better understanding of the pathophysiology and intricacies of the RAAS in septic shock has led to the use of exogenous angiotensin II as a new therapeutic agent. In this review, we report a multinational and multi-disciplinary expert panel discussion on the role and implications of RAAS modulation in sepsis and the use of exogenous angiotensin II. The panel proposed guidance regarding patient selection and treatment options with exogenous angiotensin II which should trigger further research.
Expert guidance now available for angiotensin II selection in sepsis; leaves open need for RCT confirmation before routine use.
No takes yet. Share an insight, caveat, or question.
Legrand et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: